Streetbeat News

ORKA

Oruka Therapeutics, Inc.

http://www.orukatx.com

Industry

Biotechnology

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Leerink Swann has initiated coverage on Oruka Therapeutics with an Outperform rating and set a price target of $44.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:30 am

LifeSci Capital has initiated coverage on Oruka Therapeutics with an Outperform rating and set a price target of $41.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:21 pm

TD Cowen has initiated coverage on Oruka Therapeutics with a Buy rating, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:02 am

Jefferies has initiated coverage on Oruka Therapeutics with a Buy rating and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 12:52 pm

Oruka Therapeutics has announced a PIPE financing deal, raising approximately $200 million. The company is offering 5.6 million shares at $23 each, 2,439 Series A non-voting convertible preferred stock at $23,000 each, and pre-funded warrants for 680,000 shares at $22.999 each.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:09 am

Oruka Therapeutics shares rose after Wedbush initiated coverage with an Outperform rating and a $40 price target.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 5:28 pm

Wedbush analyst David Nierengarten has initiated coverage on Oruka Therapeutics with an Outperform rating and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 3:34 pm

The trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. This suggests that trading activities for a specific asset, potentially ORKA, were temporarily paused and are now set to resume.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:55 pm

Oruka Therapeutics has completed its merger with ARCA Biopharma and will begin trading under the ticker ORKA. The company also appointed CRISPR CEO Samarth Kulkarni as Chairman. A $275 million private placement was completed, and the company has approximately 46.3 million shares outstanding.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:06 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.